CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-16 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +18,000 | $2.22 | $40K | 154,748 |
| 2024-01-16 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −18,000 | $10.93 | $197K | 136,748 |
| 2024-01-16 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −18,000 | 361,469 | ||
| 2024-01-16 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 993,514 |
| 2024-01-16 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $10.45 | $261K | 968,514 |
| 2024-01-16 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,072,635 | ||
| 2024-01-09 | Li Dean Y Director | Sale 10b5-1 | −28,038 | $13.65 | $383K | 421,962 |
| 2024-01-09 | Li Dean Y Director | Sale 10b5-1 | −962 | $14.03 | $13K | 421,000 |
| 2024-01-09 | Borgeson Blake Director | Sale 10b5-1 | −6,303 | $13.21 | $83K | 7,358,169 |
| 2024-01-09 | Borgeson Blake Director | Sale 10b5-1 | −13,751 | $13.81 | $190K | 7,344,418 |
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 801,328 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 791,328 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 822,578 |
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Sale | −30,853 | $9.49 | $293K | 791,725 |
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion | +4,000 | 4,000 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Sale | −4,000 | $9.51 | $38K | 0 |
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion | +20,000 | 20,000 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Sale | −20,000 | $9.51 | $190K | 0 |
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion | +1,000 | 1,000 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Sale | −1,000 | $9.49 | $9K | 0 |
Page 26 of 41 · 805 trades